Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy. [electronic resource]
Producer: 20120619Description: 1543-50 p. digitalISSN:- 1532-1827
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal -- immunology
- Antibodies, Monoclonal, Humanized -- therapeutic use
- Antibody-Dependent Cell Cytotoxicity
- CD55 Antigens -- chemistry
- CD59 Antigens -- chemistry
- Complement Activation
- Cystadenocarcinoma, Serous -- genetics
- Cytotoxicity, Immunologic
- Down-Regulation
- Female
- Flow Cytometry
- Humans
- In Situ Hybridization, Fluorescence
- Membrane Cofactor Protein -- genetics
- Middle Aged
- Prognosis
- RNA, Small Interfering -- genetics
- Real-Time Polymerase Chain Reaction
- Receptor, ErbB-2 -- genetics
- Trastuzumab
- Uterine Cervical Neoplasms -- genetics
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.